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Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S286GvHD was more frequent in group A( 18 versus16)
patients(P: 0.37). Five relapses were observed in group A and
9 relapses occurred in group B (P: 0.23). The main causes of
death in both groups were relapse (50%) and aGvHD (22.2%).
The median follow-up time was 24 months. Diseaseefree
survival (DFS) was 47 in group A and 37 months (P: 0.34) in
groups B. The study showed overall survival (OS) of 45 and 34
months (P: 0.71) in groups A and B, respectively.
Conclusion: Even without considering the costs of treat-
ment, it is recommended that AML patients directly undergo
transplantation after being treated with a standard chemo-
therapy regimen (7+3) because no differences in DFS, OS,
GvHD were observed between the two groups.408
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Relapse is the most common cause of allogeneic stem cell
transplantation (SCT) failure. Non-cycling, chemoresistant
leukemic stem cells (LSCs) are thought to contribute to dis-
ease relapse and have been shown to be dependent on
signaling through the Hedgehog (Hh) pathway. Targeting
this pathway represents a rational approach to the eliminate
LSCs to prevent relapse. PF-04449913 (Pﬁzer) is a small
molecule inhibitor of the transmembrane G protein-coupled
Smoothened (SMO) receptor, a key mediator of the Hh
pathway. PF-04449913 demonstrates single-agent activity in
relapsed leukemias.
We designed an open label, Phase 2 study employing PF-
04449913 in acute leukemia andMDS patients following SCT.
Eligibility requirements include enrollment within 28-50
days of SCT, engraftment, and high risk of relapse. High
relapse risk is deﬁned for myeloablative conditioning regi-
mens in acute leukemia as the presence of persistent
morphologic disease or minimal residual disease (MRD) at
the time of transplant as measured by ﬂow cytometry, cy-
togenetics, or FISH, and, for MDS, persistent disease at the
time of transplant with poor risk cytogenetics. For non-
myeloablative transplants, patients with a relapse risk score
>0, as deﬁned by the Fred Hutchinson Cancer Research
Center scoring system, are also included. Patients receive
consecutive 28-day cycles of PF-04449913 at 100 mg/day for
up to one year or until toxicity or relapse. Twenty-eight pa-
tients are required for an 80% power to detect an estimatedFigure.one year relapse free survival improvement from a null hy-
pothesis of 30% to 53%.
To date 13 patients have enrolled including 9 AML, 3 ALL, and 1
MDS (7 myeloablative and 6 non-myeloablative). Median
follow up is 176 days. Three patients (one of whom relapsed)
required dose reductions to 50 mg due to muscle cramps and
dysgeusia, andonepatientdiscontinueddue tomuscle cramps.
No other signiﬁcant toxicities were attributed to the drug.
Three patients relapsed including one morphologic, one MRD,
and one with graft failure (developing prior to enrollment on
study)with subsequent relapse.Onepatient diedofGVHD, and
12 remain alive. One patient has completed the study and 7
remain on studywith amedianof 6 cycles completed (range 1-
10). Preliminary data suggests that PF-04449913 is well toler-
ated early post-SCT and may reduce relapse rates.409
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We recently found that early pre-emptiveDLI with
donor CD4+ T-Cells cultured in rapamycin (T-Rapa) allowed
allo-engraftment after low-intensity ﬂudarabine plus cyclo-
phosphamide (Cy) host conditioning (Blood, 2013). To eval-
uate further reductions in conditioning intensity, we
conducted a pilot clinical trial of allogeneic HSCT using a
novel regimen of pentostatin and low-dose, daily cyclo-
phosphamide (PC) in patients with refractory renal cell car-
cinoma (RCC, n¼10; Table 1). After PC conditioning, patients
received high dose sirolimus, a T-replete matched related
